AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

January 17, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 17, 2020--

The “Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) is an enzyme encoded by the ENPP2 gene. It stimulates migration of melanoma cells. It has a role in induction of parturition. It is involved in cell proliferation and adipose tissue development.

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Gastrointestinal, Immunology, Central Nervous System, Cardiovascular, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Idiopathic Pulmonary Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Systemic Sclerosis (Scleroderma), Breast Cancer, Inflammation, Inflammatory Bowel Disease, Lung Cancer, Multiple Sclerosis, Atherosclerosis, Chronic Obstructive Pulmonary Disease (COPD), Fibrosis, Ischemic Stroke, Kidney Fibrosis, Liver Fibrosis, Melanoma, Metastatic Lung Cancer, Musculoskeletal Pain, Osteoarthritis Pain, Ovarian Cancer, Pain, Solid Tumor, Thyroid Cancer and Visceral Pain.

The latest report Ectonucleotide Pyrophosphatase Phosphodiesterase Family Member 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics development with respective active and dormant or discontinued projects.

Scope

Reasons to buy

Key Topics Covered:

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/p43fe2

View source version on businesswire.com:https://www.businesswire.com/news/home/20200117005273/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/17/2020 08:48 AM/DISC: 01/17/2020 08:48 AM

http://www.businesswire.com/news/home/20200117005273/en